[PHIC PHILHEALTH CIRCULAR NO. 05, S. 2004, January 21, 2004]

AMENDMENTS AND CLARIFICATIONS TO PHILHEALTH CIRCULAR NO. 34, S. 2003

Please be guided by the following amendments and clarifications to PhilHealth Circular No. 34 s. 2003 titled Reimbursement of Claims for Drugs Listed in the PNDF Vol. 1 6th Edition and PhilHealth List of Reimbursable Drugs (Positive List):

1. In October 2003, the Department of Health furnished us with the partial list of drugs included in the latest edition of the Philippine National Drug Formulary (PNDF) which is the 6th edition. The annexes of Circular No. 34 provide a summary of the similarities and differences between the 5th edition and 6th edition of the PNDF. The drugs and drug preparations could either be:

i. delisted - listed in the 5th edition but removed in the 6th edition,

ii. added - not found in the 5th edition but included in the 6th edition, or

iii. retained - listed in both the 5th and 6th edition

It is possible though that only a certain drug preparation is delisted or added while the drug per se is retained. Drugs and drug preparations so affected are listed in Annexes 1 and 2 of PhilHealth Circular No. 34, s. 2003.

2. For the tables on annexes 1 and 2, the first column contains the drugs in their generic/international non-proprietary names (INN); the second column contains the drug's respective routes of administration; and the third column contains the preparations that specify the drug's dosage strength, dosage form and packaging.

3. Section A of Annex 1 contains the drugs, in their generic name, that has been newly included in the 6th edition of the PNDF. These drugs therefore are additional compensable drugs.

4. Section B of Annex 1 contains the newly included preparations of retained drugs in the 6th edition of the PNDF. These preparations therefore are additional compensable drug preparations.

5. Section A of Annex 2 contains the drugs, in their generic names, that have been delisted in the 6th edition of the PNDF and are therefore

no longer compensable.

6. Section B of Annex 2 contains the **delisted preparations of retained drugs** in the 6th edition of the PNDF. These preparations therefore are no longer compensable. **The retained or newly included preparations of the drugs listed in this section are still compensable.**

7. Further, the following corrections and clarifications on Annexes 1 and 2 are hereby made for your guidance:

ANNEX 1 - New Drugs and Drug Preparations Included in the PNDF Vol. 1 6th Edition

A. Additional Compensable Drugs (by November 1, 2003)

Section 3.0 Anti-Infectives (page 1 of Annex 1)

1. Didanoside should read as **Didanosine.**

Section 5.0 CARDIOVASCULAR DRUGS (page 1 of Annex 1)

1. Add the following drugs, which are already included in the 5th Edition of the PNDF but are classified under a different category. In the latest edition, they are newly listed under Section 5.0 Cardiovascular Drugs.

GENERIC NAME	ROUTE	PREPARATION
Atropine	Inj.:	1 mg/ml, 1 ml ampul (IM, IV, SC) (as sulfate)
Enoxaparin	Inj.:	20 mg/0.2 ml, 40 mg/0.4 ml, 60 mg/0.6 ml and 80 mg/0.8 ml pre-filled syringe (SC); 100 mg/ml, 1 ml vial (SC)
Unfractionated Heparin	Inj.:	1,000 IU/ml and 5,000

IU/ml, 5 ml vial (IV, IV infusion, SC) (as sodium salt)

Warfarin	Oral:	1 mg, 2.5 mg
		and 5 mg
		tablet

B. Additional Compensable Drug Preparations (by November 1, 2003)

Section 3.0 Anti-Infectives

(page 2 of Annex 1)

1. Add to the list the following preparation of Chloroquine:

GENERIC NAME	ROUTE	PREPARATION
Chloroquine	Inj.:	50 mg/ml, 20 ml vial (IM, IV) (as diphosphate

1. **Delete** from the list the following **preparation** of Clindamycin:

GENERIC NAME	ROUTE	PREPARATION
Clindamycin	Inj.:	150 mg/ml, 4 ml vial (IM, IV) as phosphate)

Section 5.0 CARDIOVASCULAR DRUGS (page 3 of Annex
1)

1. Add to the list the following preparation of metoprolol:

GENERIC NAME	ROUTE	PREPARATION
Metoprolol	Oral:	10 mg tablet (as tartrate)